Sign In

Anne Christine Heerdegen, MSc, PhD

Epidemiology | Global Health | Access to Medicines

Anne Christine Heerdegen, MSc, PhD, is a postdoctoral researcher specializing in Global Market Access within the Oncology division at Johnson & Johnson Innovative Medicine. Her academic background includes a Master's and a Doctorate in fields related to epidemiology and global health, equipping her with expertise in access to medicines and healthcare systems.

In her current role, she focuses on strategies to enhance patient access to innovative cancer therapies. Heerdegen has also been involved in research that addresses public health challenges, particularly in oncology. Her contributions extend to various publications and presentations at conferences, showcasing her commitment to advancing healthcare solutions.

Heerdegen is active on LinkedIn under the username acish, where she shares insights related to her work and the broader field of oncology. Her professional journey reflects a strong dedication to improving health outcomes through research and collaboration.

Highlights

Dec 2 · linkedin

Too many people are missing out on new technologies to treat cancer, particularly in low- and middle income countries. #Kudos to #Novartis for signing this #voluntarylicense agreement with MPP that will increase access to a much needed cancer treatment for patients in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines and Tunisia.

Sep 26 · linkedin

Digital health technologies play an increasingly important role in ensuring #accesstocare for hard-to-reach populations globally #sdg3

My former colleagues at Boston University School of Public Health and I have examined how pharmaceutical companies apply #digitalhealth in their global health access programs that aim to enhance access to #NCD care in low – and middle-income countries.

Our recently published findings may 1) inform key stakeholders about innovative opportunities to promote access to life-changing care and 2) facilitate improvements in #digitalhealthgovernance. Robust measurement and transparent reporting on industry-led DHT implementations in LMICs is critical to prevent duplicative or redundant technologies that may end up overburdening local health systems.

https://lnkd.in/eCq2uDQZ

Related Questions

What are some of Anne Christine Heerdegen's notable achievements in her career?
How did Anne Christine Heerdegen transition from Boston University to Johnson & Johnson Innovative Medicine?
What specific projects has Anne Christine Heerdegen worked on in oncology?
Can you provide examples of Anne Christine Heerdegen's contributions to global health?
What is Anne Christine Heerdegen's role in the Global Market Access team at Johnson & Johnson?
Anne Christine Heerdegen, MSc, PhD
Anne Christine Heerdegen, MSc, PhD, photo 1
Anne Christine Heerdegen, MSc, PhD, photo 2
Add to my network

Location

Greater Boston